A ONCE-DAILY ORAL JAK inhibitor indicated for the treatment of adults and pediatric patients 12+ years of age with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.1
ABBVIE IS COMMITTED
TO SUPPORTING YOUR PATIENTS
National Commercial Formulary coverage under the pharmacy benefit as of August 2022.2
Enroll your patients in
Complete and send the enrollment and prescription form to the patient's specialty pharmacy and to RINVOQ Complete. Once enrolled, patients can benefit from:
As with all no-charge programs, considerations include:
- Fixed program duration‖
- Ongoing PAs and appeals to maintain eligibility
- Program-mandated distribution process
‡Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing health care professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.
Have questions about RINVOQ Complete or need support over the phone?
Call 1-877-COMPLETE (1-877-266-7538)
Commercial patients not yet covered are eligible to get RINVOQ from
Once enrolled in RINVOQ Complete, commercially eligible patients experiencing initial coverage delays or denials may be able to access their prescribed treatment at no charge while coverage is being established.†
Insurance specialists are there to help your patients navigate their coverage.
Eligible, commercially insured patients can save on their RINVOQ prescription and required lab tests.‡
*Formulary Definitions: Preferred means the product is placed on the plan's preferred formulary. Based on formulary status under the pharmacy benefit.
†Terms and Conditions apply. This benefit covers RINVOQ® (upadacitinib) alone or, for rheumatology patients, RINVOQ plus one of the following medications: ethotrexate, leflunomide, or hydroxychloroquine. Benefit also covers certain lab tests to monitor for specific parameters as recommended in the product label where the full cost is not covered by patients’ insurance through the Complete Rebate program (Maximum savings limit of $1,000.00 per year applies). Eligibility: Available to patients with commercial insurance coverage for RINVOQ who meet eligibility criteria. Co-pay assistance program is not available to patients receiving reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the RINVOQ Complete Savings Card and patient must call RINVOQ Complete at 1-800-2RINVOQ to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the RINVOQ Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Subject to all other terms and conditions, the maximum annual benefit that may be available solely for the patient’s benefit under the co-pay assistance program is $14,000.00 per calendar year. The actual application and use of the benefit available under the co-pay assistance program may vary on a monthly, quarterly, and/or annual basis, depending on each individual patient’s plan of insurance and other prescription drug costs. With the exception of patients enrolled in a health plan subject to Maine insurance law, patients who are members of insurance plans that claim to reduce or eliminate their patients' out-of-pocket co-pay, coinsurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. By redeeming this card, you acknowledge that you are an eligible patient and that you understand and agree to comply with the terms and conditions of this offer. To learn about AbbVie’s privacy practices and your privacy choices, visit
§Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.
‖Program duration may be limited by manufacturer terms and conditions.